PRIMARY OPEN-ANGLE GLAUCOMA (POAG)
Clinical trials for PRIMARY OPEN-ANGLE GLAUCOMA (POAG) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY OPEN-ANGLE GLAUCOMA (POAG) trials appear
Sign up with your email to follow new studies for PRIMARY OPEN-ANGLE GLAUCOMA (POAG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Add-On therapy tested to slow Glaucoma's vision damage
Disease control CompletedThis study tested whether adding the drug Mexidol to standard glaucoma treatment could help protect the optic nerve and slow vision loss. It involved 80 people with advanced primary open-angle glaucoma whose eye pressure was already controlled. Researchers measured changes in eye…
Matched conditions: PRIMARY OPEN-ANGLE GLAUCOMA (POAG)
Phase: PHASE4 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Apr 04, 2026 00:05 UTC
-
New glaucoma drug aims to shield eyes from irreversible damage
Disease control CompletedThis study tested whether a drug called Mexidol could help control primary open-angle glaucoma, a leading cause of irreversible blindness. Researchers compared different doses of the drug against a placebo in 102 patients with moderate to advanced stages of the disease. The main …
Matched conditions: PRIMARY OPEN-ANGLE GLAUCOMA (POAG)
Phase: PHASE2 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC